Literature DB >> 1654454

Neutralizing antibodies induced by recombinant vaccinia virus expressing varicella-zoster virus gpIV.

A Vafai1, W N Yang.   

Abstract

Monoclonal antibodies generated against varicella-zoster virus (VZV) glycoprotein I (gpI) also recognize VZV gpIV (A. Vafai, Z. Wroblewska, R. Mahalingam, G. Cabirac, M. Wellish, M. Cisco, and D. Gilden, J. Virol. 62:2544-2551, 1988). To determine whether the virus-neutralizing activity of these antibodies belongs to gpI, gpIV, or both, the open reading frame encoding gpIV was inserted into the vaccinia virus genome. Immunoprecipitation of recombinant vaccinia virus-infected cells with anti-gpIV monoclonal antibody yielded synthesis and processing of gpIV similar to those expressed in VZV-infected cells. Antibodies raised against VVgpIV in a rabbit recognized both native gpI and gpIV and neutralized VZV infectivity. In addition, antibodies raised against recombinant vaccinia virus carrying VZV gpI neutralized VZV infection. These results indicate a structural relationship between VZV gpI and gpIV and show that gpI and gpIV each induce virus-neutralizing antibody.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1654454      PMCID: PMC249072     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  25 in total

1.  Humoral and cellular immunity to varicella-zoster virus glycoprotein gpI and to a non-glycosylated protein, p170, in the strain 2 guinea-pig.

Authors:  A M Arvin; S M Solem; C M Koropchak; E Kinney-Thomas; S G Paryani
Journal:  J Gen Virol       Date:  1987-09       Impact factor: 3.891

2.  Antibodies to varicella-zoster virus glycoproteins I, II, and III in leukemic and healthy children.

Authors:  P S LaRussa; A A Gershon; S P Steinberg; S A Chartrand
Journal:  J Infect Dis       Date:  1990-09       Impact factor: 5.226

Review 3.  Immunology of the varicella-zoster virus glycoproteins.

Authors:  C Grose; V Litwin
Journal:  J Infect Dis       Date:  1988-05       Impact factor: 5.226

4.  New common nomenclature for glycoprotein genes of varicella-zoster virus and their glycosylated products.

Authors:  A J Davison; C M Edson; R W Ellis; B Forghani; D Gilden; C Grose; P M Keller; A Vafai; Z Wroblewska; K Yamanishi
Journal:  J Virol       Date:  1986-03       Impact factor: 5.103

5.  The complete DNA sequence of varicella-zoster virus.

Authors:  A J Davison; J E Scott
Journal:  J Gen Virol       Date:  1986-09       Impact factor: 3.891

6.  Expression of varicella-zoster virus glycoprotein I in cells infected with a vaccinia virus recombinant.

Authors:  G Cabirac; D Gilden; M Wellish; A Vafai
Journal:  Virus Res       Date:  1988-05       Impact factor: 3.303

7.  Cell-mediated immune responses after immunization of healthy seronegative children with varicella vaccine: kinetics and specificity.

Authors:  B Watson; P M Keller; R W Ellis; S E Starr
Journal:  J Infect Dis       Date:  1990-10       Impact factor: 5.226

8.  Monoclonal antibodies against three major glycoproteins of varicella-zoster virus.

Authors:  C Grose; D P Edwards; W E Friedrichs; K A Weigle; W L McGuire
Journal:  Infect Immun       Date:  1983-04       Impact factor: 3.441

9.  Western blot analysis of antibody to varicella-zoster virus.

Authors:  L Dubey; S P Steinberg; P LaRussa; P Oh; A A Gershon
Journal:  J Infect Dis       Date:  1988-05       Impact factor: 5.226

10.  Synthesis and processing of glycoproteins of Varicella-Zoster virus (VZV) as studied with monoclonal antibodies to VZV antigens.

Authors:  T Okuno; K Yamanishi; K Shiraki; M Takahashi
Journal:  Virology       Date:  1983-09       Impact factor: 3.616

View more
  2 in total

1.  Mutational analysis of the role of glycoprotein I in varicella-zoster virus replication and its effects on glycoprotein E conformation and trafficking.

Authors:  S Mallory; M Sommer; A M Arvin
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

2.  Specific lysis of targets expressing varicella-zoster virus gpI or gpIV by CD4+ human T-cell clones.

Authors:  Z Huang; A Vafai; J Lee; R Mahalingam; A R Hayward
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.